PDCD1 and metastatic melanoma: In the subsequent analysis, our signature was an effective prognostic biomarker in both metastatic urothelial patients who received anti-PD-L1 treatment in the IMvigor210 cohort and metastatic melanoma patients receiving anti-PD-1 therapy in Liu’s cohort (Figure 11A,D).